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Despite membership in the same genus, Mycobac-
terium tuberculosis and the nontuberculous mycobacteria
(NTM) are strikingly different. M tuberculosis is transmit-
ted from person to person by the airborne route. The
NTM (once designated anonymous, atypical, unclassified,
and “mycobacteria other than M tuberculosis”) are ubiquitous
in nature (soil, water, and dust), and human-to-human
transmission does not occur. M tuberculosis tends to invade
the host and cause disease, whereas NTM colonize with
infrequent tissue invasion. Many drugs effective against
M tuberculosis are ineffective for NTM infections.
At ﬁrst glance, it seems paradoxical that M tuberculosis,
infecting more than a billion people worldwide, rarely
causes infection in the severely immunocompromised host
undergoing bone marrow transplantation. This oddity
stems from the fact that 95% of the cases of tuberculosis
are in developing countries, where bone marrow transplan-
tation is done infrequently, if at all. In developed countries,
where bone marrow transplantation is done often, the inci-
dence of tuberculosis is low. That the incidence in trans-
plant recipients is proportional to the incidence of tubercu-
losis in the general population is demonstrated by the
report of Budak-Alpdogan and colleagues from Turkey,
where tuberculosis is endemic (35 cases per 100,000) [1].
They found tuberculosis to be some 40 times more common
in allogeneic stem cell transplant recipients (5 cases per 351
recipients) than in the general population. In comparison, Ip
et al. [2] reported tuberculosis at the rate of 10 cases in 183
bone marrow transplant recipients in Hong Kong. The cur-
rent rate for new cases of tuberculosis in the US is about 7
cases per 100,000 in the general population, and fewer than
1.0% of bone marrow transplant recipients have the infec-
tion. The overall incidence of new cases of tuberculosis in
the US has declined over the last decade, and one-third to
one-half of these cases are patients with HIV infection. Of
great concern now is the emergence of multiple drug–
resistant strains of M tuberculosis indirectly related to the
AIDS epidemic.
Even though infection rates are low, constant vigilance
is needed to detect and prevent the infection in transplant
recipients. Ip et al. [2] found risk factors to include allo-
geneic transplants, graft-versus-host disease, and total body
irradiation. Recent developments have greatly facilitated the
diagnosis of tuberculosis. New tests to identify M tuberculosis
RNA or DNA in respiratory tract specimens permit identiﬁ-
cation within 24 to 48 hours, with speciﬁcity of more than
95%. But even with rapid tests, acid-fast stains and cultures
should always be done to obtain organisms for testing of
drug susceptibility. Also, restriction fragment length poly-
morphism analysis of isolates may provide useful epidemio-
logic information. Tuberculin skin testing of the recipient
and donor are warranted and isoniazid (INH) prophylaxis is
indicated for positive reactors, as recommended by Budak-
Alpdogan et al. [1]. Additionally, health care workers in con-
tact with transplant recipients should be regularly tested for
tuberculosis.
The important study of Gaviria et al. [3] suggests that
the incidence of NTM infections in bone marrow transplant
recipients has not changed over the past 2 decades. In many
countries, however, the overall prevalence of NTM infection
has increased due to the increase in numbers of immuno-
compromised patients who have AIDS or cancer or who
have undergone organ transplantation or therapy that per-
mits prolonged survival.
In great part, NTM infections in non-AIDS patients are
not life-threatening, although the morbidity is troublesome
and a few patients may progress to serious disease. None of
the 28 patients in the report by Gaviria et al. died [3]. These
results are similar to those in other studies. NTM infections
in AIDS patients, however, may be more progressive, lead-
ing to extensive pneumonitis and disseminated infection in
the blood, spleen, liver, bone marrow, lymph nodes, and
other organs. Although the current antimicrobial regimens
for therapy are cumbersome, require long-term administra-
tion, and have slow response, the majority of patients
recover. Removal of indwelling catheters from infected sites
is essential for successful treatment.
No vaccines or precautionary measures are available to
prevent NTM in transplant recipients. Chemoprophylaxis
to prevent M avium-intracellulare complex (MAC) infections
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in AIDS patients has been successful, using drugs such as
clarithromycin, azithromycin, or rifabutin singly for patients
with CD4 counts less than 100 cells per mm3. Recent stud-
ies show that azithromycin given once a week is effective in
preventing disseminated MAC infection in advanced AIDS
patients. Because of the low incidence of NTM infections at
present, there is no indication for routine NTM chemopro-
phylaxis in bone marrow transplant recipients.
With the rapidly expanding use of bone marrow trans-
plantation, relatively higher rates of tuberculosis can be
expected in recipients in developing countries, where rates of
tuberculosis are high in the general population. The rate and
extent of NTM infections will depend directly on the extent
and duration of severely impaired cell-mediated immunity
and the use and care of indwelling central catheters, because
NTM are readily available in the environment of essentially
all medical centers regardless of geographic location.
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